No Data
No Data
NeuroBo Pharmaceuticals GAAP EPS of -$2.46
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down
NeuroBo Pharmaceuticals (NRBO) said Wednesday it received the go-ahead to continue its mid-stage clinical trial of DA-1241 without modification, a treatment for metabolic dysfunction-associated steato
NeuroBo's Phase 2a Trial of DA-124 Proceeds After Safety Review
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NASDAQ:NRBO), a biotech firm specializing in cardiometabolic diseases, announced today that its Phase 2a clinical trial of DA-1241 will continue without changes following a favorable safety review.
KB Financial, BeiGene, Legend Biotech Among Premarket Gainers' Pack
Express News | NeuroBo Pharmaceuticals Receives Safety Review Committee Approval To Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 For Treatment Of MASH
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
No Data